Interstitial #lung abnormalities and the clinical course in patients with #COPD

The presence and progression of interstitial lung abnormalities (ILA) is known to be associated with a decline of lung function and increased risk of mortality. Research question We aimed to elucidate the clinical course according to ILA in patients with chronic obstructive pulmonary disease (COPD).. ..Of 363 patients with COPD, 44 and 103 patients had equivocal and definite ILA, respectively. Patients with ILA were significantly … Continue reading Interstitial #lung abnormalities and the clinical course in patients with #COPD

Mavacamten for treatment of symptomatic obstructive #hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated and are not disease-specific. We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy.. ..Between May 30, 2018, and July 12, … Continue reading Mavacamten for treatment of symptomatic obstructive #hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial